Brief: Hester Biosciences Acquires Technology From Icar - Nihsad To Develop A Low Pathogenic Avian Influenza (H9n2 Strain) Inactivated Vaccine

Hester Biosciences

28/12/2022 05:55

Dec 28 (Reuters) - Hester Biosciences Ltd  HEST.NS :
    * ACQUIRES TECHNOLOGY FROM ICAR - NIHSAD TO DEVELOP A LOW PATHOGENIC AVIAN
INFLUENZA (H9N2 STRAIN) INACTIVATED VACCINE
    * PLANS TO LAUNCH THIS VACCINE BY END OF 2023
    * HESTER INTENDS TO EXPORT THIS VACCINE TO AFRICAN AND ASIAN COUNTRIES
    * THIS VACCINE HAS A SIGNIFICANT COMMERCIAL POTENTIAL

Source text for Eikon:  ID:nBSE6wbHrc 
Further company coverage:  HEST.NS 
 ((Reuters.Briefs@thomsonreuters.com;))